Skip to content
Menu

MannKind Corporation MNKD

Full chart Compare
Set alert

Price alert · MNKD

All alert types
3.85 USD -0.10 (-2.53%)

Regular-session close

3.89 +0.04 +1.04%

After hours · Nov 20, 5:11 PM ET

3.83 Day range 4.08
2.28 52-week range 6.21
YTD
-32.10%
1 year
-22.54%

5D -0.21 (-5.13%)

3.9044.10MonTueWedThuFri3.88
Market cap
1.24B
Revenue (ttm)
413.37M
Profit margin
-18.10%
EPS (ttm)
-0.24
Shares out
321.64M
Forward P/E
24.44
YTD return
-32.10%
1-year return
-22.54%
50-day average
3.57
200-day average
3.61
Volume
4.18M
Avg volume
3.95M
Open
3.90
Previous close
3.95
Day's range
3.83 – 4.08
52-week range
2.28 – 6.21
Beta
1.09
Analysts
Strong Buy
Price target
8.33 (+116.5%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
1.75B
PEG ratio
4.39
Price / sales
3.00
Revenue growth
24.00%
Free cash flow
-6.02M
Total cash
96.61M
Total debt
578.12M
Short % of float
8.26%

Fundamental scorecard

6 of 25 checks passed on MNKD’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MNKD Revenue — quarterly 101.87M
MNKD Net income — quarterly -23.22M
MNKD EPS — quarterly -0.07

Earnings

MNKD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20260.01———
Nov 5, 2026Sep 30, 2026-0.06556-0.01+0.06+84.75%
Aug 5, 2026Jun 30, 2026-0.0075-0.06-0.05-700.00%
May 6, 2026Mar 31, 2026-0.02-0.05-0.03-150.00%
Feb 26, 2026Dec 31, 2025-0.01-0.05-0.04-400.00%
Nov 5, 2025Sep 30, 20250.010.03+0.02+200.00%

Upgrades / downgrades

MNKD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026RBC CapitalmainSector PerformSector Perform
Nov 6, 2026Cantor FitzgeraldmainOverweightOverweight
Oct 20, 2026Cantor FitzgeraldreitOverweightOverweight
Oct 19, 2026Chardan Capitalinit—Buy
Oct 7, 2026Truist SecuritiesmainBuyBuy
Sep 11, 2026Cantor FitzgeraldreitOverweightOverweight

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MNKD — it syncs with the Stock Master app.

Insider holders

MNKD insider holders
InsiderRelationLatest transactionDateShares held
AHUJA AJAY M.D.OfficerStock Award(Grant)Nov 10, 2025318,200
BINDER STEVEN BDirectorSaleSep 24, 2026713,258
CASTAGNA MICHAEL EChief Executive OfficerConversion of Exercise of derivative securityJul 14, 20262,433,780
CONSIGLIO RONALD JOSEPHDirectorStock Award(Grant)May 19, 2026132,342
HOOPER ANTHONY CDirectorStock Award(Grant)Feb 26, 2026236,153
MARASCO DOMINICOfficerStock Award(Grant)May 19, 2026344,246

Institution ownership

MNKD institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.23%32,919,459126.74MSep 29, 2026
Rubric Capital Management LP9.15%29,430,000113.31MSep 29, 2026
Frazier Life Sciences Management, L.P. 4.90%15,755,49160.66MSep 29, 2026
State Street Corporation4.69%15,096,71258.12MSep 29, 2026
Vanguard Capital Management LLC4.40%14,167,82754.55MSep 29, 2026
Geode Capital Management, LLC2.50%8,052,72131.00MSep 29, 2026

Fund ownership

MNKD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%9,327,33235.91MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.55%8,188,14831.52MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.23%7,165,91427.59MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.41%4,522,70117.41MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.10%3,526,69313.58MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.05%3,367,94412.97MAug 30, 2026